HomeTrialNCT00980538
🔬NCT00980538Phase 3ACTIVE NOT RECRUITING

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

Study Summary

The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source \[example, access program or government program\]), or local standard of care, as appropriate.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment180 participants
Primary Completion
Lead SponsorJanssen Sciences Ireland UC
Data Retrieved2026-04-11 02:55:31.549641+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.